NYU Langone Health Sets Up Research Center for Psychedelic Medicine

March 3, 2021 13:13:14

Charitable donations and support valued at more than $10 million are aiding in the progression of NYU Langone Health’s study of psychedelic medicine. Langone Health will be launching a center for psychedelic medicine, which will focus on physician training and research in this burgeoning field.

Once completed, the NYU Langone Center for Psychedelic Medicine, which will be under the Department of Psychiatry at NYU Langone, will center on a trio of transdisciplinary areas: preclinical, medicine and psychiatry research. In addition to this, the center will launch a Psychedelic Medicine Research Training Program, which will assist in the development of postdoctoral fellows and early-career faculty members into independent investigators in the psychedelic medicine field.

Michael P. Bogenschutz, a leader in the psychedelic medicine field and an NYU Grossman School of Medicine psychiatry professor who will serve as center director, explained that these resources would offer an environment in which trainees, clinicians, scientists and other personnel could contribute in various ways, to ensure that the drive to learn more about psychedelics is bolstered in the face of medical breakthroughs that are backed by science.

One of the organizations who showed support for the new psychedelic medicine center was neuropharmaceutical company MindMed, which gave $5 million. The company develops and finds new methods of treating various mental health conditions through the progression of hallucinogenic and nonhallucinogenic compounds. The company will help set up a psychedelic-based training program for clinical investigators adept in the study of treatments based off of psychedelics for critical mental health requirements. The funding from MindMed will offer pilot research funds, training and salary support for these positions: two postdoctoral and two junior faculty fellows for a five-year period.

Support to set up the center also came from Carey Turnbull, a philanthropist and business leader who pledged a $1 million gift; that was in addition to several other seven-figure donations he sourced from his network. Turnbull is the president of the Heffter Research Institute, which is a not-for-profit organization committed to backing studies on psychedelics such as psilocybin for treatment of various disorders as well as mental health conditions.

The NYU Langone Center for Psychedelic Medicine will act as NYU Langone’s center for advancement in psychedelic research. Current and past research has focused mainly on the treatment of post-traumatic stress disorderdepressionaddiction and existential and psychiatric distress linked to advanced cancer.

The chair of the NYU Langone’s Psychiatry Department, Charles R. Marmar, stated that the infrastructure as well as the support and training opportunities of the new center would catapult psychedelic research efforts to new heights.

Across the border in Canada, Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) is well placed to claim leadership position with regard to the quick development of psychedelic medicines due to its longstanding experience within the cannabis extracts market. The company will likely reap big from its foray into psychedelics since research is showing the immense potential for the component in the treatment of mental health conditions.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.